Citius Pharmaceuticals Reports First Revenue from LYMPHIR Launch: A New Conquest in Oncology

Citius Pharmaceuticals Reports First Revenue from LYMPHIR Launch

Citius Pharmaceuticals, Inc. recently achieved a remarkable milestone by announcing its first-ever reported revenue, totaling $3.9 million, from the successful launch of its innovative oncology product, LYMPHIR. This development signifies a turning point for the company, highlighting its transition into a revenue-generating entity following the launch in December 2025. Leonard Mazur, the Chairman and CEO of Citius Oncology, celebrated this accomplishment, acknowledging the extensive efforts that brought LYMPHIR to market. Citius is dedicated to enriching the cutaneous T-cell lymphoma community with critical care solutions, and the early financial success reflects the company's commitment to translating innovations into real-world value.

The launch of LYMPHIR, a targeted immunotherapy designed for adults suffering from relapsed or refractory Stage I–III cutaneous T-cell lymphoma, represents a significant addition to Citius Oncology's portfolio. This product is specifically tailored for patients who have previously undergone systemic therapy and is now making its way through the nationwide distribution network at Citius Oncology. The initial sales underscore the increasing adoption among physicians, particularly as LYMPHIR becomes available at some of the leading cancer treatment centers across the United States.

To support the commercial rollout, Citius Oncology has harnessed cutting-edge AI technology to build a commercial engagement platform. This strategic move aims to facilitate targeted interactions with a concentrated prescriber base, thereby enhancing the penetration of LYMPHIR in this niche oncology market. The company also looks beyond domestic markets, having secured agreements that would allow access to LYMPHIR via Named Patient Programs in Europe and the Middle East. This strategic approach to global accessibility is expected to open up new avenues for patient care and business growth.

Furthermore, early signals from investigator-initiated studies indicate promising opportunities for LYMPHIR. Ongoing research into the possible combination of LYMPHIR with pembrolizumab in patients with recurrent solid tumors and its incorporation into lymphodepletion regimens prior to CAR-T therapy are being closely watched. These studies could expand the clinical utility of LYMPHIR, paving the way for future label expansions.

Citius Pharmaceuticals continues to emphasize financial discipline to maintain its momentum. The company is keen on executing plans to advance its late-stage pipeline, encompassing other critical care solutions such as Mino-Lok and Halo-Lido. Both of these initiatives aim to further solidify its position as a provider of first-class medical products. Mino-Lok is specifically designed to salvage catheters in patients facing catheter-related bloodstream infections, an area of significant clinical need.

In terms of financials, the report for the first quarter of fiscal 2026 revealed a total revenue of $3.9 million from LYMPHIR sales. This was complemented by net proceeds of around $20.9 million from various equity financing offerings, signaling strong investor confidence in Citius Pharma's growth strategy. Nevertheless, the report also indicated a net loss of $8.2 million for stockholders, although it represented an improvement from the previous year's net loss.

As Citius Pharmaceuticals embarks on this new chapter, it aims to improve the quality of life for patients battling cutaneous T-cell lymphoma and beyond. The recent revenue growth not only signifies a fruitful launch but also reinforces the company's commitment to advancing patient care in oncology. With a focus on both current innovations, like LYMPHIR, and future research avenues in critical care solutions, Citius is positioned to make a lasting impact on the biopharmaceutical landscape.

Conclusion

Citius Pharmaceuticals stands at the cusp of transformative change within the medical field. By generating revenue from its new offering, LYMPHIR, and deploying strategic growth initiatives, Citius intends to significantly enhance treatment options and availability for patients in dire need. This achievement reflects not just a financial victory but a hopeful new direction in oncology.